The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | INSIGHT-MM study update: treatment patterns in first and second-line multiple myeloma
Noemi Puig, MD, PhD, University Hospital Salamanca, Salamanca, Spain, discusses updated findings from the INSIGHT-MM study (NCT02761187), which assessed treatment patterns in patients with newly diagnosed or relapsed/refractory (R/R) multiple myeloma around the world. Overall, it was shown that first-line treatments tend to be consistent, with triplet therapies incorporating bortezomib being the standard. However, second-line therapy is more varied based on location and drug availability. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Celgene: Honoraria, Speakers Bureau; Amgen, Celgene, Takeda and The Binding Site: Honoraria; Celgene, Janssen, Amgen and Takeda: Research Funding; Amgen, Celgene, Janssen and Takeda: Consultancy.
